NEW YORK, November 16, 2016 /PRNewswire/ --
Stock-Callers.com has lined up four equities in the Medical Appliancesand Equipment industry: Abbott Laboratories (NYSE: ABT), Boston Scientific Corp. (NYSE: BSX), Medtronic PLC (NYSE: MDT), and Hologic Inc. (NASDAQ: HOLX). These companies belong to the Healthcare sector which was narrowly lower in afternoon trade on
Abbott Park, Illinois headquartered Abbott Laboratories' shares gained 1.56%, closing Tuesday's trading session at $39.81. The stock recorded a trading volume of 9.26 million shares, which was above its three months average volume of 8.99 million shares. Shares of the Company are trading 1.37% below their 200-day moving average. Additionally, shares of Abbott Laboratories, which manufactures and sells health care products worldwide, have a Relative Strength Index (RSI) of 47.60.
On November 07th, 2016, Abbott announced that the Ministry of Health, Labor and Welfare in Japan has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people in Japan with coronary artery disease. Absorb is the only fully dissolving heart stent approved in Japan for the treatment of heart disease, one of the leading causes of death in Japan and worldwide. An estimated 1.73 million people in Japan (population:127 million) have heart disease, and approximately 71.7 thousand people die each year from coronary artery disease, making it the secondary leading cause of death in the country annually. Free research report on ABT is available at:
On Tuesday, shares in Marlborough, Massachusetts headquartered Boston Scientific Corp. recorded a trading volume of 9.58 million shares, which was above their three months average volume of 8.42 million shares. The stock rose 1.68%, ending the day at $21.14. The Company's shares have advanced 14.64% on an YTD basis. The stock is trading below its 200-day moving average by 2.31%. Furthermore, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 36.38.
On November 15th, 2016, Boston Scientific announced that it has acquired the gynecology and urology portfolio of Distal Access, LLC, a Salt Lake City based company that designs minimally invasive medical devices. The portfolio includes the Resectr™ Tissue Resection Device, a single-use solution designed to effectively remove uterine polyps. Specific terms of the transaction were not disclosed. The complimentary research report on BSX can be downloaded at:
Dublin, Ireland headquartered Medtronic PLC's stock finished the day 1.93% higher at $80.27. A total volume of 6.88 million shares was traded, which was higher than their three months average volume of 4.64 million shares. The Company's shares have advanced 5.41% since the start of this year. The stock is trading below its 200-day moving average by 1.93%. Additionally, shares of Medtronic, which manufactures and sells device-based medical therapies worldwide, have an RSI of 39.63.
On November 15th, 2016, Medtronic announced data supporting the strength and durability of the Endurant(TM) II/IIs1 stent graft system to treat abdominal aortic aneurysm (AAA) patients. The results, presented during the 43rd Annual Symposium of Vascular and Endovascular Issues (VEITHsymposium) in New York, were based upon new sub-analyses of Medtronic`s ENGAGE Global Registry, which enrolled more than 1,200 patients at 79 sites across six continents. With 10-year follow-up planned for all patients, ENGAGE represents the most robust post-market registry ever initiated in the study of endovascular aortic repair. Visit us today and access our complete research report on MDT at:
Shares in Marlborough, Massachusetts headquartered Hologic Inc. ended yesterday's session 3.16% higher at $37.60 with a total trading volume of 2.03 million shares. The stock is trading 4.16% above its 200-day moving average. Shares of the Company, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, the Asia-Pacific, and internationally, have an RSI of 50.88.
On November 14th, 2016, Hologic announced the launch of its next-generation NovaSure® 6mm global endometrial ablation system, the NovaSure® ADVANCED system. The system has been CE-marked and is being launched in Europe, Canada, and Australia. The NovaSure system reduces abnormal uterine bleeding by applying radiofrequency energy to the endometrium and gently removing the lining of the uterus in two minutes or less The enhancements in the NovaSure ADVANCED product are designed with the patient and physician in mind, offering a 6mm diameter to improve patient comfort and physician ease-of-use while maintaining the clinical efficacy of the trusted NovaSure system. Get free access to your research report on HOLX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All